Melanoma research breakthroughs have led to approvals in both targeted therapies for BRAF mutations and immunotherapy treatments for many cancers. Since the development of immunotherapy in the last 10 years, distant metastatic disease patients’ survival rates increased from 15% to over 50%. Fund Melanoma Research, Advance All Cancer Research Our mission is to eradicate melanoma by accelerating medical RESEARCH while EDUCATING and ADVOCATING for the melanoma community.
Since 2011, many new treatments for melanoma have become available that are given either alone or in combination, including the first treatment for ocular (eye) melanoma. To date, we have awarded almost $25 million in research grants across the disciplines of biology, immunology, prevention, diagnosis and treatment leading to patents, clinical trials and new FDA-approved treatments.
lung cancer & pleura mesothelioma
head & neck cancer
histiocytic cancer
squamous, merkel, & basal cell of skin
biliary cancer
gastric, colorectal, esophageal, & gastroesophageal junction cancers
thyroid cancer
colorectal cancer
ovarian cancer
hepatocellular & biliary cancer
Melanoma Research
Targeted Therapy
Immunotherapy
triple-negative breast cancer
lung cancer
MSH-H, dMMR or TMB-H solid tumors
renal & bladder cancer
pilocytic tumor of the brain
pediatric low-grade glioma
Hodgkins, primary mediastinal large B-cell lymphomas
endometrial & cervical cancers
glioblastoma tumor of the brain
astrocytoma of the brain
Targeted and immunotherapies have been shown to be effective for advanced disease and in patients with brain metastases but also when given with curative intent in early stage disease as neoadjuvant before surgery and adjuvant therapy after surgery.
Facebook.com/Melanoma.Research.Foundation
X.com/CureMelanoma Instagram.com/CureMelanoma
YouTube.com/CureMelanoma TikTok.com/@CureMelanoma LinkedIn.com/company/Melanoma-Research-Foundation
MELANOMA RESEARCH FOUNDATION 1420 K Street NW, 7th Floor Washington, DC 20005
Made with FlippingBook Ebook Creator